Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients

Bun Hee Lee, Seung Gul Kang, Tae Woo Kim, Heon-Jeong Lee, Ho-Kyoung Yoon, Young Min Park

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aim: Amisulpride at low dosages enhances dopaminergic neurotransmission by preferentially blocking presynaptic D2/D3 receptors. Thus, low dosages of amisulpride are expected not to increase prolactin levels. The aim of this study was to examine whether low dosages of amisulpride can increase serum levels of prolactin or not clinically in Korean patients. Method: Serum prolactin levels were measured in 20 Korean patients (12 men and eight women) with various diagnoses who were treated with less than 300 mg of amisulpride per day. Results: The mean dosage of amisulpride was 195.0 ± 51.0 mg/day, and serum level of prolactin was 76.1 ± 43.4 ng/mL. The prolactin level was significantly higher in women (110.7 ± 49.3 ng/mL) than in men (53.1 ± 15.9 ng/mL) after administering amisulpride (P = 0.021), while the dosage of amisulpride did not differ significantly between men (200.0 ± 42.6 mg/day) and women (187.5 ± 64.1 mg/day) (P = 0.576). Conclusions: The low dosages of amisulpride elevate serum prolactin level in the majority of patients. This finding indicates that the dose-reduction of amisulpride has little effect to relieve amisulpride-induced hyperprolactinemia at therapeutic dosages. Clinicians should monitor serum prolactin level even when low dosages of amisulpride are administered.

Original languageEnglish
Pages (from-to)69-73
Number of pages5
JournalPsychiatry and Clinical Neurosciences
Volume66
Issue number1
DOIs
Publication statusPublished - 2012 Feb 1

Fingerprint

Hyperprolactinemia
Psychiatry
Prolactin
Serum
sultopride
Synaptic Transmission

Keywords

  • amisulpride
  • antipsychotics
  • hyperprolactinemia
  • prolactin

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients. / Lee, Bun Hee; Kang, Seung Gul; Kim, Tae Woo; Lee, Heon-Jeong; Yoon, Ho-Kyoung; Park, Young Min.

In: Psychiatry and Clinical Neurosciences, Vol. 66, No. 1, 01.02.2012, p. 69-73.

Research output: Contribution to journalArticle

Lee, Bun Hee ; Kang, Seung Gul ; Kim, Tae Woo ; Lee, Heon-Jeong ; Yoon, Ho-Kyoung ; Park, Young Min. / Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients. In: Psychiatry and Clinical Neurosciences. 2012 ; Vol. 66, No. 1. pp. 69-73.
@article{8585a9ee3ec849928e9c56d28bf222cb,
title = "Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients",
abstract = "Aim: Amisulpride at low dosages enhances dopaminergic neurotransmission by preferentially blocking presynaptic D2/D3 receptors. Thus, low dosages of amisulpride are expected not to increase prolactin levels. The aim of this study was to examine whether low dosages of amisulpride can increase serum levels of prolactin or not clinically in Korean patients. Method: Serum prolactin levels were measured in 20 Korean patients (12 men and eight women) with various diagnoses who were treated with less than 300 mg of amisulpride per day. Results: The mean dosage of amisulpride was 195.0 {\^A}± 51.0 mg/day, and serum level of prolactin was 76.1 {\^A}± 43.4 ng/mL. The prolactin level was significantly higher in women (110.7 {\^A}± 49.3 ng/mL) than in men (53.1 {\^A}± 15.9 ng/mL) after administering amisulpride (P = 0.021), while the dosage of amisulpride did not differ significantly between men (200.0 {\^A}± 42.6 mg/day) and women (187.5 {\^A}± 64.1 mg/day) (P = 0.576). Conclusions: The low dosages of amisulpride elevate serum prolactin level in the majority of patients. This finding indicates that the dose-reduction of amisulpride has little effect to relieve amisulpride-induced hyperprolactinemia at therapeutic dosages. Clinicians should monitor serum prolactin level even when low dosages of amisulpride are administered.",
keywords = "amisulpride, antipsychotics, hyperprolactinemia, prolactin",
author = "Lee, {Bun Hee} and Kang, {Seung Gul} and Kim, {Tae Woo} and Heon-Jeong Lee and Ho-Kyoung Yoon and Park, {Young Min}",
year = "2012",
month = "2",
day = "1",
doi = "10.1111/j.1440-1819.2011.02296.x",
language = "English",
volume = "66",
pages = "69--73",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients

AU - Lee, Bun Hee

AU - Kang, Seung Gul

AU - Kim, Tae Woo

AU - Lee, Heon-Jeong

AU - Yoon, Ho-Kyoung

AU - Park, Young Min

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Aim: Amisulpride at low dosages enhances dopaminergic neurotransmission by preferentially blocking presynaptic D2/D3 receptors. Thus, low dosages of amisulpride are expected not to increase prolactin levels. The aim of this study was to examine whether low dosages of amisulpride can increase serum levels of prolactin or not clinically in Korean patients. Method: Serum prolactin levels were measured in 20 Korean patients (12 men and eight women) with various diagnoses who were treated with less than 300 mg of amisulpride per day. Results: The mean dosage of amisulpride was 195.0 ± 51.0 mg/day, and serum level of prolactin was 76.1 ± 43.4 ng/mL. The prolactin level was significantly higher in women (110.7 ± 49.3 ng/mL) than in men (53.1 ± 15.9 ng/mL) after administering amisulpride (P = 0.021), while the dosage of amisulpride did not differ significantly between men (200.0 ± 42.6 mg/day) and women (187.5 ± 64.1 mg/day) (P = 0.576). Conclusions: The low dosages of amisulpride elevate serum prolactin level in the majority of patients. This finding indicates that the dose-reduction of amisulpride has little effect to relieve amisulpride-induced hyperprolactinemia at therapeutic dosages. Clinicians should monitor serum prolactin level even when low dosages of amisulpride are administered.

AB - Aim: Amisulpride at low dosages enhances dopaminergic neurotransmission by preferentially blocking presynaptic D2/D3 receptors. Thus, low dosages of amisulpride are expected not to increase prolactin levels. The aim of this study was to examine whether low dosages of amisulpride can increase serum levels of prolactin or not clinically in Korean patients. Method: Serum prolactin levels were measured in 20 Korean patients (12 men and eight women) with various diagnoses who were treated with less than 300 mg of amisulpride per day. Results: The mean dosage of amisulpride was 195.0 ± 51.0 mg/day, and serum level of prolactin was 76.1 ± 43.4 ng/mL. The prolactin level was significantly higher in women (110.7 ± 49.3 ng/mL) than in men (53.1 ± 15.9 ng/mL) after administering amisulpride (P = 0.021), while the dosage of amisulpride did not differ significantly between men (200.0 ± 42.6 mg/day) and women (187.5 ± 64.1 mg/day) (P = 0.576). Conclusions: The low dosages of amisulpride elevate serum prolactin level in the majority of patients. This finding indicates that the dose-reduction of amisulpride has little effect to relieve amisulpride-induced hyperprolactinemia at therapeutic dosages. Clinicians should monitor serum prolactin level even when low dosages of amisulpride are administered.

KW - amisulpride

KW - antipsychotics

KW - hyperprolactinemia

KW - prolactin

UR - http://www.scopus.com/inward/record.url?scp=84862950065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862950065&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1819.2011.02296.x

DO - 10.1111/j.1440-1819.2011.02296.x

M3 - Article

VL - 66

SP - 69

EP - 73

JO - Psychiatry and Clinical Neurosciences

JF - Psychiatry and Clinical Neurosciences

SN - 1323-1316

IS - 1

ER -